News and Trends 23 Aug 2022 Ocelot Bio receives FDA Orphan Drug Designation for lead candidate for treatment of hepatorenal syndrome …capped maximal efficacy to avoid excessive vasoconstriction that can be seen with full agonists and which can lead to ischemic events. By eliminating V2 activity, OCE-205 treatment is designed to… August 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Tokyo scientists reveal possible new direction for getting rid of cancer cells …have found that intact autograph vacuoles are indispensable in mediating competitive elimination of the cancer cells. They also noted perturbation of autophagy prevents cell elimination which encourages cancer cell… September 19, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 Mar 2023 5 advancements in kidney disease research over the past year …decline. However, findings detailed limitations such as the drug having increased the risk of adverse events, which led to modifying the original protocol to a lower dose regimen. Although improvements… March 9, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2022 Treatment for cancer-associated thrombosis fast-tracked by FDA A clinical-stage biotechnology company that develops therapies for cardiovascular and metabolic diseases today (July 11) announced it has been granted fast track designation by the US Food and Drug Administration… July 11, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 CSL closer to gene therapy treatments for hemophilia B patients in Europe …to be generally well-tolerated with no serious treatment-related adverse events. The positive opinion from the CHMP will now be reviewed by the European Commission, which has the authority to approve… December 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 1 Mar 2018 Just a Single Dose of this Drug Boosts the Survival of Heart Failure Patients …weak.” As this process is implicated in 80% of heart failure cases, the biotech has targeted this aspect of the disease. Berlin Cures’ drug prevents antibodies from damaging the heart…. March 1, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2017 A Brand New Outlook on Induced Pluripotent Stem Cells …development company that pairs up with biotechs and pharmaceutical institutions to study and develop therapies in fields, such as neuroscience, diabetes, oncology and infectious diseases. With so much to learn… July 17, 2017 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Asthma in the spotlight as Upstream Bio starts trial and UK universities propose new long-term treatment Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, has initiated a phase 1b multiple ascending dose study of UPB-101 in asthma patients with the dosing of… August 9, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2018 Novo Nordisk Partners Dutch Biotech to Prevent Cardiovascular Disease …also cut the frequency of major cardiovascular events by over 20% compared with placebo. Furthermore, Novo recently launched a collaboration with fellow Danish company Embark Biotech, with the aim of… December 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Mar 2020 Alnylam Gets Second RNAi Drug Approval from EMA US biotech Alnylam Pharmaceuticals has succeeded in getting its second RNAi drug — for treatment of rare, inherited liver diseases — approved by the European Medicines Authority just months after… March 3, 2020 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 Aelis Farma’s first trial for cognitive disorder drug for Down Syndrome patients …and 55 years old. The results obtained have shown that all the doses of AEF0217 were well tolerated by healthy volunteers with no serious adverse reaction. Only three adverse events… November 15, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 Astellas gastric cancer drug meets phase 3 primary endpoint …frequent treatment-emergent adverse events (TEAEs) were nausea and vomiting. Detailed results will be presented at a future scientific congress and submitted for publication. An important milestone in Astellas’ gastric cancer… December 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email